Unknown

Dataset Information

0

Control over Imidazoquinoline Immune Stimulation by pH-Degradable Poly(norbornene) Nanogels.


ABSTRACT: The reactivation of the innate immune system by toll-like receptor (TLR) agonists holds promise for anticancer immunotherapy. Severe side effects caused by unspecific and systemic activation of the immune system upon intravenous injection prevent the use of small-molecule TLR agonists for such purposes. However, a covalent attachment of small-molecule imidazoquinoline (IMDQ) TLR7/8 agonists to pH-degradable polymeric nanogels could be shown to drastically reduce the systemic inflammation but retain the activity to tumoral tissues and their draining lymph nodes. Here, we introduce the synthesis of poly(norbornene)-based, acid-degradable nanogels for the covalent ligation of IMDQs. While the intact nanogels trigger sufficient TLR7/8 receptor stimulation, their degraded version of soluble, IMDQ-conjugated poly(norbornene) chains hardly activates TLR7/8. This renders their clinical safety profile, as degradation products are obtained, which would not only circumvent nanoparticle accumulation in the body but also provide nonactive, polymer-bound IMDQ species. Their immunologically silent behavior guarantees both spatial and temporal control over immune activity and, thus, holds promise for improved clinical applications.

SUBMITTER: Kockelmann J 

PROVIDER: S-EPMC7304817 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Control over Imidazoquinoline Immune Stimulation by pH-Degradable Poly(norbornene) Nanogels.

Kockelmann Johannes J   Stickdorn Judith J   Kasmi Sabah S   De Vrieze Jana J   Pieszka Michaela M   Ng David Yuen W DYW   David Sunil A SA   De Geest Bruno G BG   Nuhn Lutz L  

Biomacromolecules 20200416 6


The reactivation of the innate immune system by toll-like receptor (TLR) agonists holds promise for anticancer immunotherapy. Severe side effects caused by unspecific and systemic activation of the immune system upon intravenous injection prevent the use of small-molecule TLR agonists for such purposes. However, a covalent attachment of small-molecule imidazoquinoline (IMDQ) TLR7/8 agonists to pH-degradable polymeric nanogels could be shown to drastically reduce the systemic inflammation but ret  ...[more]

Similar Datasets

| S-EPMC4961133 | biostudies-literature
2022-02-05 | GSE185997 | GEO
| S-EPMC10607756 | biostudies-literature
| S-EPMC8267846 | biostudies-literature
| S-EPMC4751432 | biostudies-other
| PRJNA771672 | ENA
| S-EPMC5976466 | biostudies-literature
| S-EPMC4190050 | biostudies-literature
| S-EPMC6035766 | biostudies-literature
| S-EPMC6183067 | biostudies-literature